argenx (NASDAQ:ARGX - Get Free Report) released its quarterly earnings results on Thursday. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60, Zacks reports. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.
argenx Trading Down 0.3 %
argenx stock traded down $2.06 during trading hours on Monday, hitting $622.61. 179,295 shares of the stock traded hands, compared to its average volume of 273,702. The firm's 50-day moving average price is $642.62 and its two-hundred day moving average price is $591.22. The company has a market cap of $37.83 billion, a PE ratio of -707.51 and a beta of 0.58. argenx has a one year low of $349.86 and a one year high of $678.21.
Analyst Ratings Changes
Several research analysts have recently commented on ARGX shares. HC Wainwright lifted their price objective on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a report on Friday. Deutsche Bank Aktiengesellschaft downgraded argenx from a "hold" rating to a "sell" rating in a report on Friday, January 17th. Wedbush reiterated an "outperform" rating and issued a $655.00 price objective on shares of argenx in a report on Tuesday, December 3rd. Truist Financial reiterated a "buy" rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $661.17.
Read Our Latest Analysis on argenx
About argenx
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
